RxDoctor Payments Data

Thomas Berbos, MD

Ophthalmology · Helena, MTNPI 1710963517

Payments from drug & device makers

What this record shows

This record is dominated by other: $3,336 of the $4,533 with a category attached, or 73.6%. Carl Zeiss Meditec, Inc. accounts for 75.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $3,514 and has fallen 89.4% since, to $371 in 2025. Among ophthalmology clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,533in general payments, 2019–2025

Across 22 payments — averaging $206.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$3K
  • Astellas Pharma US Inc$223
  • Regeneron Healthcare Solutions, Inc.$211
  • Thea Pharma Inc.$200
  • Eyepoint US, Inc.$124
  • Novartis$108
  • plus $267 from 6 others

What the payments were for

  • Travel & lodging$281%
  • Food & beverage$94921%
  • Education$2004%
  • Gifts$190%
  • Other$3,33674%

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,533 in reported general payments places this provider in the 90th percentile of 52 ophthalmology providers in Montana.

See all ophthalmology providers in Montana

Medicare billing

Part B allowed, 2024
$4,444,133
Medicare patients
1,920
Services billed
29,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine109$113,683
LumiganBimatoprost43$28,179
Cyclosporine39$16,013
CombiganBrimonidine Tartrate/Timolol28$10,484
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$8,605
RhopressaNetarsudil Mesylate29$8,510
Latanoprost649$7,868
IlevroNepafenac17$6,473
Prednisolone Acetate179$6,068
Alphagan PBrimonidine Tartrate18$5,493
ErythromycinErythromycin Base271$3,904
Travoprost14$3,055
Timolol Maleate83$2,905
SimbrinzaBrinzolamide/Brimonidine Tart13$2,574
Brimonidine Tartrate27$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$104$157,838198 claims
Aerie Pharmaceuticals, Inc.Rhopressa$41$8,51029 claims
NovartisIlevro$108$6,47317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 ophthalmology providers in Montana.

Other ophthalmology in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →